Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3)
Complete Title: An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults with Advanced Hepatocellular Carcinoma (HCC).
Trial Phase: I/II
Investigator: William Harris
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (= 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents. Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now conducting Phase II to further confirm the safety profile of ECT204 and evaluate its efficacy.
Keywords:
- Liver Cancer; Carcinoma, Hepatocellular
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.